Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
Cue Biopharma (Nasdaq: CUE) is set to present at The Promise of Interleukin-2 Therapy Conference in Paris, France, from September 4-7, 2024. Two key presentations are scheduled:
1. On September 6, Dr. Steven Quayle will present preclinical data on CUE-401, a novel bispecific fusion protein that induces and expands regulatory T cells through co-delivery of IL-2 and TGF-β.
2. On September 7, Dr. Matteo Levisetti will discuss the clinical safety and efficacy of the company's lead oncology programs CUE-101 and CUE-102, which selectively target IL-2 to tumor-specific T cells for enhanced efficacy and safety profiles.
These presentations highlight Cue Biopharma's innovative approach in developing therapeutic biologics to modulate disease-specific T cells.
Cue Biopharma (Nasdaq: CUE) si prepara a presentare alla Conferenza sulla Promessa della Terapia con Interleuchina-2 a Parigi, Francia, dal 4 al 7 settembre 2024. Sono previste due presentazioni chiave:
1. Il 6 settembre, il Dr. Steven Quayle presenterà dati preclinici su CUE-401, una nuova proteina di fusione bispecifica che induce ed espande le cellule T regolatorie attraverso la co-somministrazione di IL-2 e TGF-β.
2. Il 7 settembre, il Dr. Matteo Levisetti discuterà della sicurezza clinica e dell'efficacia dei principali programmi oncologici dell'azienda CUE-101 e CUE-102, che mirano selettivamente all'IL-2 per cellule T specifiche del tumore, migliorando così efficacia e profili di sicurezza.
Queste presentazioni evidenziano l'approccio innovativo di Cue Biopharma nello sviluppo di biologici terapeutici per modulare le cellule T specifiche per la malattia.
Cue Biopharma (Nasdaq: CUE) se prepara para presentar en la Conferencia sobre la Promesa de la Terapia con Interleucina-2 en París, Francia, del 4 al 7 de septiembre de 2024. Se han programado dos presentaciones clave:
1. El 6 de septiembre, el Dr. Steven Quayle presentará datos preclínicos sobre CUE-401, una nueva proteína de fusión bispecífica que induce y expande las células T regulatorias a través de la co-administración de IL-2 y TGF-β.
2. El 7 de septiembre, el Dr. Matteo Levisetti discutirá la seguridad clínica y la eficacia de los principales programas oncológicos de la empresa CUE-101 y CUE-102, que tienen como objetivo seleccionar IL-2 para células T específicas del tumor, mejorando así la eficacia y los perfiles de seguridad.
Estas presentaciones destacan el enfoque innovador de Cue Biopharma en el desarrollo de biológicos terapéuticos para modular células T específicas de la enfermedad.
큐 바이오파마 (Nasdaq: CUE)는 2024년 9월 4일부터 7일까지 프랑스 파리에서 열리는 인터루킨-2 치료의 약속 컨퍼런스에서 발표할 예정입니다. 두 개의 주요 발표가 예정되어 있습니다:
1. 9월 6일, 스티븐 퀘일 박사가 CUE-401에 대한 전임상 데이터를 발표할 예정이며, 이는 IL-2와 TGF-β의 동시 전달을 통해 조절 T 세포를 유도하고 확장하는 새로운 이중 특이적 융합 단백질입니다.
2. 9월 7일, 마테오 레비세티 박사가 회사의 주요 종양학 프로그램 CUE-101 및 CUE-102의 임상 안전성과 효능에 대해 논의할 예정이며, 이는 특정 종양 T 세포에 IL-2를 선택적으로 표적하여 효능과 안전성 프로필을 향상시키는 것입니다.
이 발표들은 질병 특정 T 세포를 조절하기 위한 치료 생물학 개발에서 큐 바이오파마의 혁신적인 접근 방식을 강조합니다.
Cue Biopharma (Nasdaq: CUE) va présenter à la Conférence sur la Promesse de la Thérapie par Interleukine-2 à Paris, France, du 4 au 7 septembre 2024. Deux présentations clés sont prévues :
1. Le 6 septembre, le Dr Steven Quayle présentera des données précliniques sur CUE-401, une protéine de fusion bispécifique novatrice qui induit et développe des cellules T régulatrices grâce à la co-administration d'IL-2 et de TGF-β.
2. Le 7 septembre, le Dr Matteo Levisetti discutera de la sécurité clinique et de l'efficacité des principaux programmes oncologiques de l'entreprise CUE-101 et CUE-102, qui ciblent spécifiquement l'IL-2 vers les cellules T spécifiques aux tumeurs pour améliorer l'efficacité et les profils de sécurité.
Ces présentations mettent en avant l'approche innovante de Cue Biopharma dans le développement de biologiques thérapeutiques pour moduler les cellules T spécifiques aux maladies.
Cue Biopharma (Nasdaq: CUE) wird auf der Konferenz "Die Versprechen der Interleukin-2 Therapie" in Paris, Frankreich, vom 4. bis 7. September 2024 präsentieren. Zwei wichtige Vorträge sind geplant:
1. Am 6. September wird Dr. Steven Quayle präklinische Daten zu CUE-401 vorstellen, einem neuartigen bispezifischen Fusionsprotein, das regulatorische T-Zellen durch die Co-Gabe von IL-2 und TGF-β induziert und erweitert.
2. Am 7. September wird Dr. Matteo Levisetti die klinische Sicherheit und Wirksamkeit der führenden Onkologie-Programme des Unternehmens CUE-101 und CUE-102 erörtern, die IL-2 gezielt auf tumorspezifische T-Zellen ausrichten, um die Wirksamkeit und Sicherheitsprofile zu verbessern.
Diese Präsentationen heben den innovativen Ansatz von Cue Biopharma bei der Entwicklung therapeutischer Biologika hervor, die krankheitsspezifische T-Zellen modulieren.
- None.
- None.
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that members of its management team will deliver two presentations at The Promise of Interleukin-2 Therapy Conference, taking place September 4-7, 2024 in Paris, France.
Presentation Details
Date and Time: Friday, September 6, 2024, 4 p.m. CET
Presentation Title: CUE-401: A Novel IL-2/TGF-beta fusion protein for the induction & expansion of FOXP3+ regulatory T Cells
Presenter: Steven Quayle, Ph.D., vice president & head, Biology Research & Translational Medicine, Cue Biopharma
Dr. Quayle will present preclinical data on our first-in-class bispecific fusion protein, CUE-401, which induces and expands regulatory T cells (Tregs) through the co-delivery of interleukin 2 (IL-2) and transforming growth factor beta (TGF-β), and how this approach differentiates from other Treg-directed therapies.
Date and Time: Saturday, September 7, 2024, 9 a.m. CET
Presentation title: Clinical safety and efficacy of TCR-specific engagers that selectively target IL-2 to tumor-specific T cells
Presenter: Matteo Levisetti, M.D., chief medical officer, Cue Biopharma
Dr. Levisetti will discuss how the company’s lead oncology programs CUE-101 and CUE-102, representative of the CUE-100 series of Immuno-STAT™ biologics, enable selective targeting of the cytokine IL-2 to tumor specific T cells for enhanced efficacy and safety profiles.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company’s belief regarding the potential benefits and applications of its drug candidates and programs, including the transformational potential of the company’s Immuno-STAT™ platform to accomplish its mission of developing breakthrough immunotherapies to establish a new standard of care in the treatment of cancer and autoimmune disease; the near-term and intermediate value creation potential of its autoimmune programs; the company’s intention to preserve the value of its oncology programs; the company’s business strategies, plans and prospects, including those related to the prioritization of CUE-401 and CUE-501, and the potential benefits of the company’s program prioritization and realignment on its burn rate; and the cash runway of the company and the sufficiency of the company’s cash and cash equivalents to fund its operations. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “promise” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s ability to shift its focus to its autoimmune assets and achieve the cost savings that it is projecting; the company’s limited operating history, limited cash and a history of losses; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company’s operations and clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to obtain adequate financing to fund its business operations in the future and ability to continue as a going concern; the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
FAQ
What is Cue Biopharma presenting at the Interleukin-2 Therapy Conference in September 2024?
When and where is Cue Biopharma (CUE) presenting at the Interleukin-2 Therapy Conference?
What is CUE-401 and how does it work according to Cue Biopharma's presentation?
How do Cue Biopharma's CUE-101 and CUE-102 programs work in oncology?
